Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...

Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...

Roller-coaster healthcare stock Hims & Hers Health (NYSE: HIMS), whose stock got devastated last week by worries that it ...

Apostrophe, a Bay Area telehealth company focused on skin care, shut down after almost four years under the Hims & Hers ...

Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operation | Hims & Hers ...

BlueChew offers only generic versions of ED medication, which are more affordable. Hims also offers the name brand medications as well as services outside of ED treatments, so it’s more ...

Former US Army Sgt. Mark Millich’s sex drive plummeted — and his genitals shrank and changed shape after taking popular hair-loss drug finasteride.